The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
 
E. Jason Abel
No Relationships to Disclose
 
Jose A. Karam
Stock and Other Ownership Interests - Alimera Sciences; MedTek
Honoraria - Pfizer; Roche/Genentech
Consulting or Advisory Role - Pfizer; Roche/Genentech
Research Funding - Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Philippe E. Spiess
Honoraria - UptoDate
Other Relationship - NCCN
 
Jay D. Raman
No Relationships to Disclose
 
Wade J. Sexton
No Relationships to Disclose
 
Logan Zemp
No Relationships to Disclose
 
Alyssa Bilotta
No Relationships to Disclose
 
Dattatraya Patil
No Relationships to Disclose
 
Glenn O. Allen
No Relationships to Disclose
 
Kate V. Lauer
No Relationships to Disclose
 
Daniel D. Shapiro
No Relationships to Disclose
 
Surena F. Matin
Honoraria - Taris BioMedical; Urogen pharma
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; QED Therapeutics; Taris BioMedical
Research Funding - AT&T
Travel, Accommodations, Expenses - MSD
 
Christopher G. Wood
Leadership - Kidney Cancer Association
Honoraria - Argos Therapeutics; Merck; Pfizer
Speakers' Bureau - Argos Therapeutics; Pfizer
Research Funding - Argos Therapeutics; Pfizer
Travel, Accommodations, Expenses - Argos Therapeutics; Merck